pxs share price, page-9

Primaus,

I dont know why you get such a perverse pleasure from downramping this stock, but you obviously do! Perhaps it has something to do with your history as an investor in PXS.

Quite clearly your sentiment has changed from the majority of posts that you where making prior to the negative opinion earlier in the year.

But don't try and destabilise other peoples believes in their investments because you are disconcerted with a stock that you have lost money on!

I am all in favour of providing balanced opinions, but I do have an issue with people who consistently post towards the negative. You once seemed to have a very positive opinion of PXS (judging by the posts below and many more in the past) and this was only 6-8 months ago.

Now you have swung to a completely negative opinion ! If anyone is in need of balancing their opinions on a given stock - it might be you ; P

**examples of Primaus posts -

"I cant really see how EMA will reject the drug - its proven to work without any serious side effects over a good range of CF patients in both phIII and long term open label trials.

My long term target for this stock is around $10.. I expect this to be reached 2013 (FY13 / FY14)"

Primaus post no. 6503916

"I talked to mgt few days ago.. from the discussion my view is that the EMA decision will come out on the April decision.

RE: valuation.. with a achieveble PE of 2-3 in FY13
I would not be selling PXS in a TO situation for less than $10 within the next 12 months.

Also to note - there are patients who have been using Bronhitol for more than 3 years under compassionate use. Sustained benefit without major side effects over the long term is well established.

At peak market penetration I expect 40,000 users using the drug for CF alone. At a min. of $10,000 per annum I would expect PXS to upwards of $400M in revenues in CF alone."

Primaus post 6377887